Cartesian Therapeutics Inc.

RNAC | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.12

+$0.18 (+2.27%)

Sep 22, 2026, 11:07 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.27%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $238.53M

1D Range

8 8.25

52W Range

5.60 11

Valuation (TTM)

PE -1.36

PB -1.86

EV/EBITDA -0.61

Valuation (NTM)

Forward PE N/A

Forward PEG -0.03

Price Target $25

Cash Flow

FCF Yield -33.5%

SBC Adj. FCF Yield -37.5%

SBC Impact -11.8%

Margins

Gross Margin -766.4%

Operating Margin -6679.7%

FCF Margin -5291.5%

Growth (CAGR)

Revenue 3Y | 5Y -68.8% | -50.0%

Dil EPS 3Y | 5Y 117.8% | -16.3%

FCF 3Y | 5Y -10.4% | -7.0%

Returns

ROA -48.3%

ROE 141.4%

ROIC -30.8%

Financial Health

Net Cash

$136.6M

Current Ratio 7.48

Interest Coverage -115.80

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an au...

Sector Healthcare

Industry Biotechnology

Employees 75

IPO Date Jun 21, 2016

Website cartesiantherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$25

Upside

+207.88%

Buy (5)

Hold (0)

Sell (0)

Analyst Details ➞